Drug Watch
This detailed and up-to-date list is made possible by the hard work and research performed by the Hepatitis B Foundation. Please help us continue to offer this kind of essential resource for the treatment of hepatitis B with a donation toward our important programs. Donate here.
To learn more about the drug development process, click here.
Compounds in Development for Chronic Hepatitis B
Updated September 25, 2024
FAMILY/DRUG NAME |
MECHANISM |
COMPANY |
WEBSITE |
|
||||||||||||||||||||
| Interferons: Mimic infection-fighting immune substances naturally produced in the body | ||||||||||||||||||||||||
| Intron A (Interferon alfa 2b) | Immunomodulator | Merck, USA | merck.com | Approved 1991 | ||||||||||||||||||||
|
Pegasys (Peginterferon alfa 2a) |
Immunomodulator |
Approved 2005 |
||||||||||||||||||||||
| Nucleos(t)ide Analogues: Interfere with viral DNA polymerase used for HBV replication | ||||||||||||||||||||||||
|
Epivir (Lamivudine) *Generics available |
Inhibits viral DNA polymerase | GlaxoSmithKline (GSK) | gsk.com | Approved 1998 | ||||||||||||||||||||
| Hepsera (Adefovir dipivoxil) *Generics available | Inhibits viral DNA polymerase | Gilead Sciences, USA | gilead.com | Approved 2002 | ||||||||||||||||||||
|
Baraclude (Entecavir) *Generics available |
Inhibits viral DNA polymerase | Bristol-Myers Squibb, USA | bms.com | Approved 2005 | ||||||||||||||||||||
| Tyzeka (Telbivudine) *Generics available | Inhibits viral DNA polymerase | Novartis, USA | novartis.com | Approved 2006 | ||||||||||||||||||||
| Viread (Tenofovir) *Generics available | Inhibits viral DNA polymerase | Gilead Sciences | gilead.com | Approved 2008 | ||||||||||||||||||||
| Vemlidy (TAF or tenofovir alfenamide) | Prodrug of Tenofovir | Gilead Sciences | gilead.com | Approved 2016 | ||||||||||||||||||||
|
Levovir (Cledvudine) |
Inhibits viral DNA polymerase | Bukwang, S. Korea | bukwang.co.kr | Approved 2006 in S. Korea | ||||||||||||||||||||
|
Direct Acting Antivirals: Targets the virus and interferes in the HBV replication process |
||||||||||||||||||||||||
|
Silencing RNA’s (siRNAs): Interferes and destroys viral RNA |
||||||||||||||||||||||||
|
VIR-2218 (Elebsiran) |
RNAi gene silencer |
Vir Biotech with |
Phase II |
|||||||||||||||||||||
|
Xalnesiran (RG6346, |
RNAi gene silencer |
Phase II |
||||||||||||||||||||||
|
Imdurisan (AB-729) |
RNAi gene silencer |
Phase II | ||||||||||||||||||||||
|
BW-20507 |
RNAi gene silencer |
Phase II |
||||||||||||||||||||||
|
ALG-125755 |
RNAi gene silencer |
Holding for new partner |
||||||||||||||||||||||
|
BB-103 |
RNAi gene silencer |
benitec.com | Preclinical | |||||||||||||||||||||
|
JNJ-3989 (ARO-HBV) |
RNAi gene silencer |
gsk.com | Phase II | |||||||||||||||||||||
|
HT-101 |
RNAi gene silencer |
www.hepathera.com/eng | Phase I (outside USA) | |||||||||||||||||||||
|
Entry Inhibitors: Interferes with HBV getting into liver cells |
||||||||||||||||||||||||
|
Bulevirtide (Hepcludex) |
Entry inhibitor |
Phase III |
||||||||||||||||||||||
|
Capsid or Core Inhibitors: Interferes with the viral DNA protein shield |
||||||||||||||||||||||||
|
ZM-H1505R |
Capsid inhibitor |
Phase II |
||||||||||||||||||||||
|
EDP-514 |
Capsid inhibitor |
Phase I |
||||||||||||||||||||||
|
ALG-000184 |
Capsid inhibitor |
Phase I | ||||||||||||||||||||||
|
ABI-H4334 |
Capsid inhibitor |
Phase I | ||||||||||||||||||||||
|
CS12088 |
Capsid inhibitor |
Preclinical | ||||||||||||||||||||||
|
HBsAg Inhibitors: Interferes with production of HBV surface antigen (sAg) |
||||||||||||||||||||||||
|
REP 2139 |
sAg inhibitor |
Phase II |
||||||||||||||||||||||
|
Antisense Molecules: Binds to the viral mRNA to prevent it from turning into viral protein |
||||||||||||||||||||||||
|
Bepirovirsen |
HBV Antisense |
Phase III |
||||||||||||||||||||||
|
AHB-137 |
HBV Antisense |
Phase I |
||||||||||||||||||||||
|
||||||||||||||||||||||||
|
Immunologicals: Targets the human immune system to attack the HBV virus |
||||||||||||||||||||||||
|
Therapeutic Vaccine Technology used to stimulate the immune system as a treatment |
||||||||||||||||||||||||
|
VBI-2601 (BRII-179) |
Therapeutic vaccine |
VBI Vaccines with |
Phase II | |||||||||||||||||||||
|
VVX001 |
Therapeutic vaccine |
Phase II |
||||||||||||||||||||||
|
GSK 3528869A |
Therapeutic vaccine |
Phase II | ||||||||||||||||||||||
|
VTP-300 |
Therapeutic vaccine |
Barinthus Biotherapeutics, UK (formerly Vaccitech) |
Phase II |
|||||||||||||||||||||
|
CVI-HBV-002 |
Therapeutic vaccine |
Phase I/II |
||||||||||||||||||||||
|
HB-400 (GS2829/GS6779) |
Therapeutic vaccine |
hookipapharma.com | Phase I | |||||||||||||||||||||
|
ISA104 |
Therapeutic vaccine |
isa-pharma.com | Phase I | |||||||||||||||||||||
|
VRON-0200 |
Therapeutic vaccine |
viriontx.com | Phase I | |||||||||||||||||||||
| CLB-3000 |
Therapeutic vaccine |
Clear B Therapeutics, USA | clearbtherapeutics.com | Phase I | ||||||||||||||||||||
| CARG-201 | Therapeutic vaccine | CaroGen, USA | carogencorp.com | Preclinical | ||||||||||||||||||||
|
TherVacB |
Therapeutic vaccine |
Phase I | ||||||||||||||||||||||
|
PRGN-2013 |
Therapeutic vaccine |
precigen.com | Preclinical | |||||||||||||||||||||
|
HBV vaccine |
Therapeutic vaccine |
astrivax.com | Preclinical | |||||||||||||||||||||
|
Compounds that activate the innate immune system |
||||||||||||||||||||||||
|
Selgantolimod (GS9688) |
TLR-8 agonist |
Phase II |
||||||||||||||||||||||
|
Ruzotolimod (RG7854) |
TLR-7 agonist |
Phase II | ||||||||||||||||||||||
|
CB06 |
TLR-8 agonist |
core-biopharma.com | Phase I | |||||||||||||||||||||
|
GSK 5251738 |
TLR-8 agonist |
gilead.com | Phase I | |||||||||||||||||||||
|
PRTX007 |
TLR-7 agonist |
www.primmunerx.com | Phase I | |||||||||||||||||||||
|
Cavrotolomid |
TLR9-agonist |
Blue Jay
|
bluejaytx.com | Phase I | ||||||||||||||||||||
|
YS-HBV-002 |
Activator of TLR3, RIG1, MDA5 |
ysbiopharma.com | Preclinical | |||||||||||||||||||||
|
Monoclonal Antibodies: Neutralize or bind the HBV proteins to reduce infection |
||||||||||||||||||||||||
|
VIR-3434 |
Monoclonal antibody | Vir Biotech with Brii Biosciences, USA |
vir.bio and briibio.com |
Phase II | ||||||||||||||||||||
| Burfiralimab (IgG4) | Monoclonal antibody | ImmuneMed, South Korea | immunemed.co.kr/eng | Phase II | ||||||||||||||||||||
|
BJT-778 |
Monoclonal antibody | Blue Jay Therapeutics, USA | bluejaytx.com | Phase I | ||||||||||||||||||||
|
RG6449 |
Monoclonal antibody | Roche | roche.com | Phase I | ||||||||||||||||||||
|
GIGA-2339 |
Polyclonal antibody | GigaGen, USA | gigagen.com | Phase I | ||||||||||||||||||||
|
HT-102 |
Monoclonal antibody | Hepa Thera, PR China | www.hepathera.com/eng | Preclinical | ||||||||||||||||||||
|
Checkpoint Inhibitors: Stimulate exhausted T-cell recognition of HBV-Infected cells |
||||||||||||||||||||||||
|
ASC22 (KN035 or Envafolimab) |
PDL1 inhibitor | Ascletis Pharma, PR China | ascletis.com | Phase II | ||||||||||||||||||||
|
RG6084 |
PDL1 inhibitor | Roche | roche.com | Phase II | ||||||||||||||||||||
|
AB-101 |
PDL1 inhibitor | Arbutus, USA | arbutusbio.com | Phase I | ||||||||||||||||||||
|
Other Immunologicals |
||||||||||||||||||||||||
|
IMC-I109V |
T-cell Receptor | Immunocore, UK and USA | immunocore.com | Phase I | ||||||||||||||||||||
|
Additional HBV Drugs Under Investigation |
||||||||||||||||||||||||
|
GSK 4388067A |
Targeted immunotherapy | GSK, USA | gsk.com | Phase II | ||||||||||||||||||||
|
APG-1387 |
Apoptosis inducer | Ascentage, PR China |
ascentagepharma.com | Phase II | ||||||||||||||||||||
|
GSK 3965193 |
PAPD5/PAPD7 inhibitor |
GSK, USA | gsk.com | Phase I | ||||||||||||||||||||
|
DF-006 |
Small molecule | Drug Farm, PR China | drug-farm.com | Phase I | ||||||||||||||||||||
|
AB359 |
CD8 IL-2 immunotherapy | Asher Biotherapeutics, USA | Preclinical | |||||||||||||||||||||
|
BJT-628 |
Small molecule | Blue Jay Therapeutics, USA | bluejaytx.com | Preclinical | ||||||||||||||||||||
|
Hepatitis Delta Virus (HDV)- A virus that co-infects people already infected with HBV |
||||||||||||||||||||||||
|
Hepcludex (Bulevirtide formerly Myrcludex B) |
Entry inhibitor |
EU approved 2023 Phase III USA |
||||||||||||||||||||||
|
Lonafarnib |
Prenylation inhibitor |
Holding for new partner |
||||||||||||||||||||||
|
REP 2139 |
HBsAg inhibitor |
Phase II |
||||||||||||||||||||||
|
VIR-2218 + VIR 3434 |
RNAi gene silencer + Monoclonal antibody |
Phase II | ||||||||||||||||||||||
|
BJT-778 |
Monoclonal antibody |
Phase II | ||||||||||||||||||||||
|
ABI-6250 |
Entry inhibitor |
assemblybio.com | Preclinical | |||||||||||||||||||||
|
Elebsiran (VIR-2218) Tobevibart (VIR-3434) |
RNAi + mAb |
vir.bio | Phase II | |||||||||||||||||||||
If you are a person with hepatitis B who is looking for clinical trial or other research opportunities, please visit our patient and provider opportunities page here.